These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Infliximab: new indication. Severe Crohn's disease in children: many unknowns. Prescrire Int; 2008 Aug; 17(96):145. PubMed ID: 19489184 [TBL] [Abstract][Full Text] [Related]
5. Adalimumab: new indication. Severe Crohn's disease: a second TNF alpha antagonist, subcutaneous administration. Prescrire Int; 2008 Aug; 17(96):137. PubMed ID: 19480092 [No Abstract] [Full Text] [Related]
6. Infliximab (Remicade) for Crohn's disease. Med Lett Drugs Ther; 1999 Feb; 41(1047):19-20. PubMed ID: 10076592 [No Abstract] [Full Text] [Related]
7. Infliximab therapy in Crohn's disease: safety issues. Hommes DW; van Deventer SJ Neth J Med; 2003 Apr; 61(4):100-4. PubMed ID: 12852717 [TBL] [Abstract][Full Text] [Related]
8. [Indications and results of infliximab in Crohn's disease]. Karoui S; Boubaker J; Filali A Tunis Med; 2004 Dec; 82(12):1057-63. PubMed ID: 15822505 [TBL] [Abstract][Full Text] [Related]
9. Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. CON: "lifetime use" is an awfully long time. Loftus EV Am J Gastroenterol; 2005 Jul; 100(7):1435-8. PubMed ID: 15984960 [No Abstract] [Full Text] [Related]
10. Infliximab (Remicade), a new biological treatment for Crohn's disease. D'Haens GR Ital J Gastroenterol Hepatol; 1999; 31(6):519-20. PubMed ID: 10575573 [TBL] [Abstract][Full Text] [Related]